IBN Announces From Lab to Launch Podcast Featuring Clene Inc. CEO Rob Etherington

May 1, 2024

IBN Announces From Lab to Launch Podcast Featuring Clene Inc. CEO Rob Etherington

IBN, a multifaceted communications organization engaged in connecting public companies with the investment community, today announces that Rob Etherington, President, Director and CEO of late clinical-stage biopharmaceutical company Clene Inc. (NASDAQ: CLNN), recently appeared on From Lab to Launch, a podcast sharing the inspiring stories of founders, investors, scientists, engineers and pioneers in the life sciences sector.

The podcast, hosted by Meg Sinclair, is available for on-demand listening on From Lab to Launch.

During the interview, Etherington discussed Clene’s work to address the critical unmet medical need relating to neurodegenerative diseases.

“The human nervous system is complex and highly metabolically active. To put it into context, our brain is about two to five percent of our body weight, but it is responsible for about 25 percent of our energy utilization every day. That includes about 20 percent of oxygen consumption and 20-25 percent of glucose utilization. The neurons themselves depend on the mitochondria for all of the energy required to do what we take for granted – moving, walking, talking, eating, chewing and breathing. But with neurodegenerative diseases, including ALS, these essential aspects of life start to be taken away.”

“The World Health Organization predicts that neurodegenerative diseases – amyotrophic lateral sclerosis (ALS), multiple sclerosis, Parkinson’s and others – will become the second-most prevalent cause of death in the next 20 years. So, it’s pretty obvious that a therapeutic breakthrough is urgently needed. Clene is pioneering catalytic nanotherapeutics to treat these diseases. We target improvement of mitochondrial function via the catalytic activity of our asset, CNM-Au8, to improve nicotinamide adenine dinucleotide, an essential energy metabolite, and to reduce reactive oxygen species, which are a byproduct of energy production… CNM-Au8 is pioneering a new way to restore and protect the way the neurons work.”

“Most drug development is small molecule chemistry. That’s how it was for basically 100 years. Then, in the last few decades, biologics have taken their place beside small molecule. Clene is doing neither of these. We’re intersecting physics and material science at nanoscale – small enough to cross the blood-brain barrier – to drive energy into the neurons.”

Throughout the interview, Etherington continued to discuss CNM-Au8, detailing both current and potential target applications for the nanotherapeutic, before exploring some of the challenges in developing novel therapeutics.

Learn more by listening to the full episode on From Lab to Launch.

About IBN

IBN is a cutting edge corporate communications and content distribution company consisting of over 60+ investor facing brands introduced to the investment public over the last 18+ years while amassing a collective audience of millions of social media followers. These distinctive investor brands aim to fulfil the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

Let's get started.

Interested in a live, online demonstration? Schedule a date and time that works for you.

Schedule a LIVE Demo

Questions about IBN and our solutions? Call or send us an email.

(310) 299-1717

You’re already more familiar with brand awareness than you might think. What’s your favorite brand of soft drink, athletic shoe, car, shampoo, streaming content provider? Chances are, you first tried those brands because of their awareness strategies. Whether it was word of mouth or a TV commercial, Facebook post, billboard or coupon, that awareness peaked interest, triggered a purchase reaction, and ideally built customer loyalty.

More About Brand Awareness

5,000+ key syndication outlets across the country. IBN’s extensive system of strategic distribution points maximizes your exposure to an audience of millions, including journalists, investors, day traders, fund managers and a multitude of other interested individuals. Now your press releases, earnings statements, branded articles, shareholder updates, corporate achievements can reach a vast and diverse nationwide audience.

More About InvestorWire

Make sure your message resonates. IBN integrates social media with traditional distribution channels to make sure your message resonates long after initial publication. This innovative model ensures that your news not only crosses the wire, but keeps reverberating via social conversation on Twitter, Facebook, LinkedIn and other social networks.

More About Social MediaIBN Social Media NetworkSocial Media Statistics & FAQs

A unique format with a traditionally different sensory input – hearing.As conferences and events continue to suffer cancellations and greatly reduced attendance, many businesses are wondering how to network with large investor audiences in the new normal. At the same time podcasts have seen a jump in popularity.

More About IBN Podcast Solutions